Stocks News

LAST PRICE
55.1300
TODAY'S CHANGE (%)
Trending Down-2.2400 (-3.9045%)

Bid / Lots
51.8600/ 1
Ask / Lots
57.4700/ 1
Open / Previous Close
56.9700 / 57.3700
Day Range
Low 54.8900
High 57.1800
52 Week Range
Low 20.5100
High 62.4000
Volume
1,944,303
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- DJ Revolution Medicines Is Maintained at Buy by Needham, from 3:49PM ET on Thursday Nov 07, 2024 by Dow Jones
  3:49PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 15:49 ET (20:49 GMT)
- DJ Revolution Medicines Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Thursday Nov 07, 2024 by Dow Jones
  3:42PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 15:42 ET (20:42 GMT)
- DJ Revolution Medicines Is Maintained at Overweight by JP Morgan, from 1:00PM ET on Thursday Nov 07, 2024 by Dow Jones
  1:00PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 13:00 ET (18:00 GMT)
- DJ Revolution Medicines Is Maintained at Overweight by Piper Sandler, from 10:10AM ET on Thursday Nov 07, 2024 by Dow Jones
  10:10AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 10:10 ET (15:10 GMT)
- Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance, from 4:50AM ET on Thursday Nov 07, 2024 by MT Newswires
  4:50AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: RVMD
  04:50 AM EST, 11/07/2024 (MT Newswires) -- Revolution Medicines (RVMD) reported a Q3 net loss late Wednesday of $0.94 per diluted share, compared with a loss of $0.99 a year earlier. Analysts polled by Capital IQ expected a loss of $0.90. The compa...

Yesterday
- DJ Ascendis Pharma Is Maintained at Buy by TD Cowen, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
  Companies Mentioned: ASND
- DJ Ascendis Pharma Price Target Maintained With a $181.00/Share by Wedbush, from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: ASND
- European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week, from 20 hours ago by MT Newswires
  20 hours ago by MT Newswires
  Companies Mentioned: BBVA, LYG, PUK, ARGX, AKTX, MREO, BCYC, BNTX, EVAX, BTI, TCBP, DBVT, ASND, CLLS, SAN, BDRX
- DJ Ascendis Pharma Is Maintained at Outperform by Oppenheimer, from 20 hours ago by Dow Jones
  20 hours ago by Dow Jones
  Companies Mentioned: ASND
- DJ Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald, from 21 hours ago by Dow Jones
  21 hours ago by Dow Jones
  Companies Mentioned: ASND
- --Oppenheimer Adjusts Ascendis Pharma A/S Price Target to $180 From $190, Maintains Outperform Rating, from 22 hours ago by MT Newswires
  22 hours ago by MT Newswires
  Companies Mentioned: ASND
- DJ Ascendis Pharma Is Maintained at Buy by Stifel, from 22 hours ago by Dow Jones
  22 hours ago by Dow Jones
  Companies Mentioned: ASND
- Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing, from 3:51AM ET on Friday Nov 15, 2024 by MT Newswires
  3:51AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: ITCI
Nov 14, 2024
- Ascendis Pharma Q3 Loss Narrows, Revenue Rises, from 4:16PM ET on Thursday Nov 14, 2024 by MT Newswires
  4:16PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: ASND
- Ascendis Pharma Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ASND

Revolution Medicines Inc
NASDAQ:RVMDUnited States

Search Criteria

Nov 7, 2024

DJ Revolution Medicines Is Maintained at Buy by Needham, from 3:49PM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Revolution Medicines Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Revolution Medicines Is Maintained at Overweight by JP Morgan, from 1:00PM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Revolution Medicines Is Maintained at Overweight by Piper Sandler, from 10:10AM ET on Thursday Nov 07, 2024 by Dow Jones

Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance, from 4:50AM ET on Thursday Nov 07, 2024 by MT Newswires

Peers Headlines

Yesterday

DJ Ascendis Pharma Is Maintained at Buy by TD Cowen, from 17 hours ago by Dow Jones

DJ Ascendis Pharma Price Target Maintained With a $181.00/Share by Wedbush, from 18 hours ago by Dow Jones

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week, from 20 hours ago by MT Newswires

DJ Ascendis Pharma Is Maintained at Outperform by Oppenheimer, from 20 hours ago by Dow Jones

DJ Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald, from 21 hours ago by Dow Jones

--Oppenheimer Adjusts Ascendis Pharma A/S Price Target to $180 From $190, Maintains Outperform Rating, from 22 hours ago by MT Newswires

DJ Ascendis Pharma Is Maintained at Buy by Stifel, from 22 hours ago by Dow Jones

Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing, from 3:51AM ET on Friday Nov 15, 2024 by MT Newswires

Nov 14, 2024

Ascendis Pharma Q3 Loss Narrows, Revenue Rises, from 4:16PM ET on Thursday Nov 14, 2024 by MT Newswires

Ascendis Pharma Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones